Sergliflozin Etabonate

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSergliflozin Etabonate
Drug Alias Name舍格列净Sergliflozini etabonas依碳舍格列净Etabonate de sergliflozine依碳酸舍格列净 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2
Therapy Area/IndicationsObesity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKissei Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsObesity

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG